Pulmonary Arterial Hypertension: Empowering Pharmacists in Treatment Decisions Towards Improved Patient Care

Evaluation and Post Test

Please note that to receive credit you must achieve a score of at least 80%.

The information that you participated will be uploaded to CPE Monitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit http://www.nabp.net/.

Question Title

1. The therapeutic target of epoprostenal is within the:

Endothelin pathway.

Prostacyclin pathway.

Glutathione pathway.

Nitric oxide pathway.

Question Title

2. Treprostinil is available in all of the following formulations except:

Oral.

Intravenous.

Subcutaneous.

Inhaled.

Question Title

3. The use of nitrates is contraindicated in patients receiving a phosphodiesterase type 5 (PDE-5) inhibitor.

True

False

Question Title

4. Pulmonary arterial hypertension is defined as having a mean pulmonary arterial pressure (mPAP) of:

>10 mmHg

>25 mmHg

>40 mmHg

>60 mmHg

Question Title

5. Current PAH therapy targets all of the following pathways except:

Vasoactive intestinal peptide (VIP)

Endothelin

Nitric Oxide

Prostacyclin